Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Yamamoto, Yuki, Kanai, Osamu, Okamura, Misato, Hashimoto, Masayuki, Nakatani, Koichi, Sawai, Satoru, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200083/
https://www.ncbi.nlm.nih.gov/pubmed/32391404
http://dx.doi.org/10.1093/ofid/ofaa126
_version_ 1783529270308503552
author Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Hashimoto, Masayuki
Nakatani, Koichi
Sawai, Satoru
Mio, Tadashi
author_facet Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Hashimoto, Masayuki
Nakatani, Koichi
Sawai, Satoru
Mio, Tadashi
author_sort Fujita, Kohei
collection PubMed
description Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.
format Online
Article
Text
id pubmed-7200083
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72000832020-05-08 Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors Fujita, Kohei Yamamoto, Yuki Kanai, Osamu Okamura, Misato Hashimoto, Masayuki Nakatani, Koichi Sawai, Satoru Mio, Tadashi Open Forum Infect Dis Brief Report Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis. Oxford University Press 2020-04-09 /pmc/articles/PMC7200083/ /pubmed/32391404 http://dx.doi.org/10.1093/ofid/ofaa126 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Hashimoto, Masayuki
Nakatani, Koichi
Sawai, Satoru
Mio, Tadashi
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title_full Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title_fullStr Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title_full_unstemmed Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title_short Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
title_sort incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200083/
https://www.ncbi.nlm.nih.gov/pubmed/32391404
http://dx.doi.org/10.1093/ofid/ofaa126
work_keys_str_mv AT fujitakohei incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT yamamotoyuki incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT kanaiosamu incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT okamuramisato incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT hashimotomasayuki incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT nakatanikoichi incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT sawaisatoru incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors
AT miotadashi incidenceofactivetuberculosisinlungcancerpatientsreceivingimmunecheckpointinhibitors

Ejemplares similares